An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases
Dutriaux, Caroline, Robert, Caroline, Grob, Jean-Jacques, Mortier, Laurent, Dereure, Olivier, Lebbe, Céleste, Mansard, Sandrine, Grange, Florent, Neidhardt, Eve-Marie, Lesimple, Thierry, Machet, Laurent, Bedane, Christophe, Maillard, Hervé, Dalac-Rat, Sophie, Nardin, Charlée, Szenik, Alexandra, Denden, Amine, Saiag, Philippe
Published in European journal of cancer (1990) (01.11.2022)
Published in European journal of cancer (1990) (01.11.2022)
Get full text
Journal Article
Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib
Saiag, Philippe, Robert, Caroline, Grob, Jean-Jacques, Mortier, Laurent, Dereure, Olivier, Lebbe, Céleste, Mansard, Sandrine, Grange, Florent, Neidhardt, Eve-Marie, Lesimple, Thierry, Machet, Laurent, Bedane, Christophe, Maillard, Hervé, Dalac-Rat, Sophie, Nardin, Charlée, Szenik, Alexandra, Denden, Amine, Dutriaux, Caroline
Published in European journal of cancer (1990) (01.09.2021)
Published in European journal of cancer (1990) (01.09.2021)
Get full text
Journal Article